A site-directed mutagenesis approach has been used to gain insight into the molecular events whereby the heptadecapeptide nociceptin binds and activates the opioid receptor-like 1 (ORL1) receptor, a G protein-coupled receptor. Alanine mutation, in the human ORL1 receptor, of transmembrane amino acid residues that are conserved in opioid receptors, Asp . The dramatic effects of the D130A mutation on nociceptin binding and activity are not reversed in the D130N mutant, whereas those of the Y131A mutation are totally suppressed in Y131F. This suggests that a negative charge at position 130, and a phenyl ring at position 131 in TM III, are critical for occupancy and/or activation of the receptor by nociceptin. Alanine replacement of glutamine 286, located at the C terminus of TM VI, yields a mutant receptor that binds nociceptin with nearly the same affinity as does the wild-type receptor (K d values of 0.13 and 0.22 nM, respectively) but, unlike the latter, is unable to mediate nociceptin inhibition of forskolininduced cAMP synthesis in recombinant Chinese hamster ovary cells (ED 50 Ͼ 10,000 nM compared with 0.8 nM at the wild-type receptor). In all respects, this mutant receptor appears to be functionally inactive, indicating that residue Gln 286 may play a pivotal role in ORL1 receptor-mediated transduction of the nociceptin signal.
Nociceptin (noc) (Meunier et al., 1995) , also known as orphanin FQ (Reinscheid et al., 1995) , a neuropeptide with multiple functions (reviewed by Henderson and McKnight, 1997; Meunier, 1997; Darland et al., 1998) , is the natural agonist of the orphan opioid receptor-like 1 (ORL1) receptor, a G protein-coupled receptor (GPCR) (Mollereau et al., 1994) . The ORL1 receptor shares high sequence similarity with opioid receptors. Likewise, noc (FGGFTGARKSARKLANQ) resembles in several respects dynorphin A (dyn), also a heptadecapeptide (YGGFLRRIRPKLKWDNQ), and the presumed natural agonist of the -opioid receptor. However, in spite of receptor homology, and common chemical features between ligands, noc and dyn appear to bind and stimulate their cognate receptors by distinct mechanisms. Studies of the structure-activity relationships of noc, based on the properties of truncated (Dooley and Houghten, 1996; Reinscheid et al., 1996; Shimohigashi et al., 1996; Butour et al., 1997; Guerrini et al., 1997) , "mutant" (Dooley and Houghten, 1996; Reinscheid et al., 1996; Guerrini et al., 1997; Calo' et al., 1998) , or hybrid noc/dyn and dyn/noc (Lapalu et al., 1997; Reinscheid et al., 1998) peptides, have now established noc[1-13]-amide as the smallest noc fragment displaying the affinity, biological potency, and ORL1 versus -opioid receptor selectivity of noc. Moreover, positively charged hexapeptides of general sequence Ac-RYY(R/K)(W/I)(R/K)-NH 2 have been shown to be potent ORL1 receptor agonists (Dooley et al., 1997) . Taken together, these data suggest that noc activ-ity may primarily reside in its positively charged R 8 KSARK domain that would therefore fulfil a "message" function (Schwyzer, 1977) . This is in marked contrast to dyn, whose capacity to induce a biological response is contained within the N-terminal Y 1 GGF sequence (Chavkin and Goldstein, 1981; Mansour et al., 1995) . The notion that noc and dyn have distinct functional architectures has gained further support from the finding that the two neuropeptides use alternative mechanisms for receptor activation. In particular, the second exofacial (e2) loop of the receptor appears to be required for stimulation of the ORL1 receptor by noc, but not for activation of the -opioid receptor by dyn (Lapalu et al., 1998; Mollereau et al., 1999) . Recently, a molecular model of the ORL1 receptor complex with noc has been built (Topham et al., 1998) , showing the N-terminal F 1 GGF tetrapeptide of noc to bind in a highly conserved transmembrane region, comprising elements from helices 3, 5, 6, and 7, that is the topological equivalent of the presumed opioid binding pocket in the -, ␦-, and -opioid receptors, and the basic R 8 KSARK segment to establish multiple interactions with the acidic e2 loop. Topham et al. (1998) have proposed that the binding energy contributed by noc [1] [2] [3] [4] may be partially uncoupled from activation mediated by the e2 loop, hence that interactions of the N-terminal tetrapeptide in the vestigial opioid pocket serve a primarily locatory function, consistent with the extremely low biological potency of most opiates at the ORL1 receptor. Thus, the TM binding cavity may serve distinct, and even inverse, functions in the ORL1 and opioid receptors, providing a differential array of binding and recognition elements for the necessary but biologically insufficient noc F 1 GGF "address" sequence in the former and for effective transduction of the Y 1 GGF "message" sequence in the latter (Mollereau et al., 1999) . Within this conceptual framework, the vestigial opioid binding pocket of the ORL1 receptor would appear better suited as a template for antagonist rather than agonist design (Mollereau et al., 1999) .
In the present study, a site-directed mutagenesis approach has been used to better delineate the role of individual amino acid residues in the transmembrane noc-binding domain of the human ORL1 (hORL1) receptor. Alanine mutation of conserved residues in ORL1 and opioid receptors results in a loss of affinity, and a commensurate loss of biological reactivity, toward noc, consistent with the provision of recognition elements to noc "address" domain. Most critical in this respect were residues Asp 130 in transmembrane segment (TM) III, and Phe 224 in TM V. We also report that alanine mutation of glutamine 286, located near the C terminus of TM VI, at the extracellular margins of the modeled F 1 GGF binding site (Topham et al., 1998) , yields a mutant receptor whose binding characteristics are undistinguishable from those of the wild-type (wt) receptor, but which is unresponsive to noc and other ORL1 receptor agonists. The mutant ORL1[Q286A] receptor is thus functionally inactive. Therefore, residue Gln 286 appears to play an important role in ORL1 receptor-mediated transduction of the noc signal.
Materials and Methods
Construction of Mutant Receptor cDNAs. Point mutations were introduced in the Bluescript SK ϩ /hORL1 construct with mutated oligonucleotides (Genosys Biotech., Pampisford, U.K.) using the ExSite PCR mutagenesis kit (Stratagene, La Jolla, CA) and Vent polymerase (New England Biolabs, Beverly, MA). To facilitate screening of the clones, an additional silent mutation was routinely incorporated into the oligonucleotides. The mutated cDNAs were custom-sequenced (Genome Express, Paris, France) and subcloned in the BsteII and XbaI sites of the eukaryotic expression vector pEFIN (Euroscreen, Brussels, Belgium).
Expression in Cell Lines. Chinese hamster ovary (CHO)-K1 cells were transfected with recombinant vectors using calcium phosphate precipitation (Chen and Okayama, 1987) or polycation-dimethyl sulfoxide (Kawai and Nishizawa, 1984) and grown in Ham's F-12 medium (Life Technology, Gaithersburg, MD) containing G418 (Life Technologies; 400 g/ml) for selection, as described previously (Mollereau et al., 1994) . Clones in which noc was able to cause maximum inhibition of forskolin-induced accumulation of cAMP (see below) were considered to express a functional receptor.
Membrane Preparation. Recombinant cells were harvested, frozen at Ϫ70°C for at least 1 h, and homogeneized in 50 mM Tris-HCl, pH 7.4, in a Potter Elvehjem tissue grinder. The nuclear pellet was discarded by centrifugation at 1,000g and the membrane fraction collected on centrifugation at 100,000g.
Binding Studies. Custom-labeled [ 3 H]noc (23 Ci/mmol; Amersham, Little Chalfont, U.K.) was used. Saturation binding and competition experiments were performed at 25°C in polypropylene tubes. Membranes (5-30 g) were incubated for 1 h with tritiated ligand alone at variable concentrations (for saturation), or with tritiated ligand at fixed concentration (1 nM) and variable concentration of unlabeled ligand (for competition), in 0.5 ml of 50 mM Tris-HCl buffer, pH 7.4, supplemented with proteinase-free BSA (to 0.1 mg/ ml; Sigma, St Louis, MO) to avoid tube wall adsorption of the radioligand. Nonspecific binding was determined in the presence of 1 M unlabeled noc. Bound radioligand was collected by filtration on polyethyleneimine-treated glass fiber filters (GF/B; Whatman, Clifton, NJ), and radioactivity counts were made in a Packard model 2100TR liquid scintillation analyzer (Packard, Meriden, CT) Intracellular cAMP Assay. Sterile hemolysis tubes were seeded with 2 ϫ 10 5 recombinant CHO cells in culture medium and incubated for ϳ16 h at 37°C. The culture medium was removed, and 200 l fresh medium containing 0.1 M adenine and 0.6 Ci [ 3 H]adenine (24 Ci/mmol; Amersham) was added. After 1 h at 37°C, the cells were rinsed with 400 l of HEPES-buffered Krebs-Ringer saline (KRH: 124 mM NaCl, 5 mM KCl, 1.25 mM MgSO 4 , 1.5 mM CaCl 2 , 1.25 mM KH 2 PO 4 , 25 mM HEPES, 8 mM glucose, 0.5 mg/ml BSA; pH 7.4) and 180 l of fresh KRH added to each tube. Intracellular accumulation of cAMP was initiated by the addition of 20 l of KRH containing 100 M forskolin (Sigma), 1 mM 3-isobutyl-1-methylxanthine (Sigma), 1 mM Ro20-1724 (Biomol Research, Plymouth Meeting, PA) and the ligand(s) to be tested at the desired concentration. The reaction was stopped after exactly 10 min at 37°C, by the addition of 20 l HCl 2.2 N and rapid mixing (Vortex). The [ 3 H]cAMP content of each tube was determined by selective batch elution on acidic alumina columns, essentially as described by Alvarez and Daniels (1992) .
Analysis of Data. Experimental data were fitted to a sigmoidal dose-response curve with variable slope parameter using the Prism program (GraphPad Software, San Diego, CA). Fitting of equilibrium binding inhibition data always yielded slope factors near unity, indicative of a homogenous population of binding sites in the membrane preparations examined. [I] 50 values (the concentration of inhibitor that halves specific binding of radioligand) were converted to K I values using the Cheng and Prussof (1973) 
Results
Several entirely conserved ORL1 receptor residues, lining the structural equivalent of the opioid binding pocket in opioid receptors (Paterlini et (Fig. 1 ). This position is occupied by different amino acid residues in the ORL1, -, ␦-, and -opioid receptors. The wt and mutant receptors were probed in terms of affinity and biological reactivity toward the known ORL1 receptor agonists, noc (Meunier et al., 1995) , [Tyr 1 ]noc , Ac-Arg-Tyr-Tyr-Lys-Trp-Lys-NH 2 (HP5; Dooley et al., 1997) , and lofentanil (Butour et al., 1997) . Specific [ 3 H]noc binding (B max in the range 1 to 5 pmol/mg protein) was readily detected in membrane preparations from transformed CHO cells expressing the wt and mutant ORL1 receptors, mutants D130A, D130N, and F224A excepted. However, the latter were able to mediate inhibition of forskolin-induced accumulation of cAMP in recombinant CHO cells (Fig. 2) , indicating that the receptor was expressed and functional. Figure 3A shows that noc Fig. 1 . Schematic representation of hORL1 receptor indicating (F) amino acid residues mutated in present study. These are also identified using one letter code followed by the receptor residue number. Conserved amino acid residues in the ORL1, -, ␦-, and -opioid receptors are underlined. N, N terminus; C, C terminus; pm, plasma membrane (box); e, extracellular loop; i, intracellular loop. Transmembrane segments are labeled with Roman numerals. The filled rectangle represents the putative disulphide bridge between cysteine residues 123 and 200. Table 1 ). The F220A mutation resulted in a Ͻ2-fold decreased affinity, and a more pronounced, although moderate reduction in biological potency (5-to 15-fold), for the four agonists. The F224A mutation was considerably more deleterious because no specific binding of ]noc showed diminished binding (2-to 4-fold reduced affinity), and biological potency (10-to 30-fold), but not efficacy. These changes are quantitatively very similar to those seen with the F220A mutant receptor. In contrast, the W276A mutant receptor could not be fully activated by HP5 and lofentanil. These ligands, which retained nearly wildtype affinity for the ORL1[W276A] mutant receptor, only produced ϳ25 and ϳ65%, respectively, of the maximum attainable inhibition level in the cAMP synthesis assay (data not shown). Both ligands, especially HP5, thus behave as low-efficacy agonists of the ORL1[W276A] mutant receptor. Indeed, HP5, in addition to exerting its own partial agonist action, was also able to prevent activation of the mutant ORL1[W276A] receptor by noc (Fig. 4A) , thereby exhibiting antagonist properties. A Schild plot of the data (Fig. 4B) was linear (r ϭ 0.99; slope ϭ 1.25), and yielded a pA 2 value of 8.1, in close agreement with the logarithmically transformed dissociation constant for HP5 (pK i ϭ 8.4).
Mutations of Gln 286 in TM VI/e3. The Q286A mutant ORL1 receptor possessed unique characteristics. As shown in Fig. 5A, ORL1 [Q286A] bound [ 3 H]noc with a high affinity (K d ϭ 0.13 nM), identical with that of the wt receptor. However, the mutant receptor was totally unresponsive to noc (ED 50 Ͼ 10 M), being unable to mediate inhibition of forskolin-induced accumulation of cAMP in recombinant CHO cells (Fig.  5B) . The retention of high affinity and sensitivity loss in ORL1[Q286A] generalized to the other ORL1 receptor agonists [Tyr 1 ]noc, HP5, and lofentanil (Table 2 ). Thus, in every respect, this mutant ORL1 receptor is functionally inactive, compared with the wt receptor. Residue Gln 286 , which is unique to the ORL1 receptor, appears to selectively stabilize the active agonist-bound receptor form, making little or no contribution to noc, [Tyr 1 ]noc, or HP5 binding per se. However, the mutation did increase the affinity for lofentanil, dyn, and etorphine by an order of magnitude (see Table 2 ). The affinity for nor-binaltorphimine (nor-BNI), a -selective opioid receptor antagonist, remained unchanged. The deleterious effect of mutating Gln 286 to alanine could be almost completely reversed in the Q286E mutant ORL1 receptor, which displayed nearly wt affinity and response toward noc, [Tyr 1 ]noc, and lofentanil. However, the HP5 peptide was ϳ13-fold less potent at the ORL1[Q286E] mutant compared with the wt receptor.
Discussion
The present study has used site-directed mutagenesis to experimentally probe the presumed transmembrane binding subsite for noc in the ORL1 receptor. Molecular modeling of the complex of receptor with noc (Topham et al., 1998) shows this subsite to be the structural equivalent of the opiate binding pocket of opioid receptors, and to host the noc Nterminal Phe 1 -Gly-Gly-Phe sequence, that closely resembles the N-terminal Tyr 1 -Gly-Gly-Phe sequence of many opioid peptides. Indeed, the existence of a vestigial opioid binding pocket within the ORL1 receptor receives strong support from the finding that relatively few point mutations in this region suffice to confer the hORL1 receptor with improved ]noc, identically, indicative of a common mode of interaction with the ORL1 receptor. Affinity and biological potency were both diminished, consistent with either uniform losses in binding energy contributions in the active and resting receptor states or pure binding effects. This supports the hypothesis that the ORL1 receptor equivalent of an opioid binding pocket assumes a mainly locatory function and that binding energy gains from the interaction of the N-terminal Phe 1 -Gly-Gly-Phe noc sequence can only be fully realized through the recruitment of interactions elsewhere with the receptor, in particular with e2 (Mollereau et al., 1999) .
The most deleterious of the five alanine substitutions in the series, with respect to noc and [ Bikker et al., 1998) . The aspartate residue equivalents in the opioid receptors have also been predicted to engage in ion-pair formation with the protonated N termini of opioid peptides (Surratt et al., 1994; Paterlini et al., 1997; Pogozheva et al., 1998) , and, on the basis of a modeling study, we have proposed a similar electrostatic interaction between Asp 130 and the N terminus of noc (Topham et al., 1998) . In the case of the ORL1 receptor, the observation that the D130E mutant does not bind noc and is inactive (data not shown) suggests that were an intimate ion-pair to form between Asp 130 and the positively charged N-terminal of noc, the presence of an extra carbon in the glutamate side chain is sufficient to disrupt the interaction. In contrast, there is no obvious steric impediment to hydrogen bond formation between the terminal NH function in the noc derivative N-acetyl-noc [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] -amide and the Asp 130 carboxylate. Consistent with this, N-acetyl-noc [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] -amide remains able to stimulate the wt receptor, albeit with an increased ED 50 . Removal of the hydrogen bond acceptor functionality in the D130A mutant leads to an inactive receptor (see Table 1 ). However, the isosteric D130N mutant, which possesses an uncharged bifunctional amide group, is unresponsive toward both noc and N-acetyl-noc [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] -amide (Table 1) . Taken together, these results suggest that the presence of a negative charge at position 130 is a necessary but insufficient requirement for ORL1 receptor activation, and so the question of whether or not there is a direct interaction of Asp 130 with the protonated N terminus of noc remains open.
In contrast to the results obtained here, Befort et al. (1996a) have provided evidence from a site-directed mutagenesis study that the aspartate residue in TM III of the ␦-opioid receptor is not necessary for binding of peptide agonists, and can be replaced by an alanine without apparent effect. Although receptor activities were not reported, the authors conclude that the aspartate does not participate in direct Coulombic interactions. Thus although the exact roles and energetic contributions of the Asp residue in TM III may differ in the ORL1 receptor and the - (Surratt et al., 1994) and ␦- (Befort et al., 1996a) opioid receptors, it is clear from our data that this residue is necessary for noc binding to the ORL1 receptor.
The present study has also identified transmembrane aromatic residues, Tyr 131 , Phe 220 , Phe 224 , and Trp 276 , as making important, although unequal contributions to binding and/or activation of the ORL1 receptor. They are conserved in the opiate binding pocket of -, ␦-, and -opioid receptors (Paterlini et al., 1997; Pogozheva et al., 1998) and the analogous hydrophobic binding pocket of the ORL1 receptor where they interact with noc[1-4] (Topham et al., 1998 (Topham et al., 1998) . However, as is the case for other aromatic residues in the TM binding pocket, nonspecific interactions with the Phe 1 and Phe 4 side chains are also evident in the model, and favorable ligand desolvation effects are likely to contribute significantly to the free energy of binding. Alanine mutation of the equivalent aromatic residues in the mouse ␦-opioid receptor (mDOR1), has been reported by Befort et al. (1996b ]noc, HP5, or lofentanil. Thus, it may be described as functionally inactive or, in the context of allostery, desensitized (Monod et al., 1965) . In the -and ␦-opioid receptors, mutations of the residues equivalent to Gln 286 in the hORL1 receptor, i.e., glutamate and tryptophan, respectively, have been shown to impair binding of -selective antagonists (Hjorth et al., 1995; Jones et al., 1998) and ␦-selective agonists (Valiquette et al., 1996) , respectively, but not of non-type-selective ligands. Although mutant receptor functionality was not examined in these studies, this residue position was concluded to be an important determinant of opioid receptor-type selectivity. Likewise, we observe that mutant ORL1[Q286A] receptor binds the opioids lofentanil, dyn, and etorphine with significantly higher affinity than does the wt receptor (see Table 2 ), suggesting that glutamine 286 may also play a role, albeit modest, in the ligand binding selectivity of the ORL1 receptor. Clearly, however, the major consequence of the Q286A mutation is functional inactivation of the receptor, indicating that residue Gln 286 may play a pivotal role in receptor transduction of the nociceptin signal. Activation of GPCRs involves positive heterotropic, longrange interactions between the agonist-and G protein-binding sites, and there is a growing body of evidence that movements of transmembrane helix VI (F in rhodopsin) are critical in this process (Dunham and Farrens, 1999 , and references therein). Within this structural context, Gln 286 occupies a strategic position, at the C terminus of TM VI in the ORL1 receptor, where it might act as a switch in a noc-promoted, TM VI-mediated structural transition of the ORL1 receptor from resting to active state. Changing this residue for an alanine residue leaves the switch in the "off" position, resulting in functional inactivation. When Gln 286 is replaced by a glutamate rather than an alanine residue, inactivation is no longer observed. These findings are consistent with the involvement of at least one hydrogen bond in selectively stabilizing the activated form of the wt receptor. The demonstration of partial or complete loss in receptor activity upon replacement of Gln 286 by a shorter amidebearing asparagine residue side chain would provide evidence in favor of hydrogen bond formation. Although modeling of the noc-ORL1 receptor complex (Topham et al., 1998) shows Gln 286 to be close to the Thr 5 side chain of the peptide, intermolecular hydrogen bonding between Gln 286 and the noc main chain, or intramolecular hydrogen bonding of Gln 286 with another residue in the activated receptor, are equally feasible.
In conclusion, the present study has provided experimental evidence for the existence, in the ORL1 receptor, of a noc transmembrane binding pocket that is the topological equivalent of the opiate binding pocket in opioid receptors. Within this pocket are the conserved aspartate residue in TM III, and several conserved aromatic residues in TMs III, IV, and VI. However, not all of the conserved aromatic residues contribute in the same way to binding and/or activity of noc and opioids in the ORL1 and opioid receptor, respectively. Identification of the allosterically desensitized, functionally inactive mutant ORL1[Q286A] receptor raises the question whether alanine mutations at the equivalent residue position in the opioid receptors also lead to functional inactivation. A total loss in binding, or complete retention of biological activity, would provide firm evidence of different activation mechanisms operating in the two receptor systems (Mollereau et al., 1999) . In the latter case, this would also delimit the extent of the agonist binding site in opioid receptors to the transmembrane region. With regard to the ORL1 receptor, the finding that Gln 286 is able to stabilize an active receptor conformation at a position level with the membrane interface, but yet does not appear to contribute to cognate agonist intrinsic binding per se, lends further support to our belief (Mollereau et al., 1999) that the transmembrane region proper of an extended noc binding site is better suited as a template for antagonist as opposed to agonist design.
